Obesity is a driver of Type 2 diabetes, hypertension, abnormal lipids and is an independent risk factor for cardiovascular events and death. The recent discovery of medications with robust ability to affect appetite is making successful and maintained weight loss a reality. In individuals with obesity, semaglutide produces 17% weight loss on average and tirzepatide, under review by the FDA, 22% weight loss on average. While cost and expertise in prescribing are still barriers to implementation in practice, these new medications offer promise in fighting the ever rising rates of obesity.

In this interview, Donna Ryan MD and Anthony N. DeMaria MD, MACC discuss When Lifestyle Isn't Enough: Surgical vs. Pharmacological Approaches for Obesity.

Related References:

• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002.

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Prevention

Keywords: ACCELLite, Obesity, Weight Loss, Dyslipidemias

< Back to Listings